Overview

Ophthalmic Drugs Market is poised to register a CAGR of 6.4% during the forecast period 2022 to 2028.

Ophthalmic medications are formulations used to treat eye illnesses such as cataract, glaucoma, colour blindness, diabetic macular edoema, cytomegalovirus (CMV) retinitis, and age-related macular degeneration (AMD). The rise in the elderly population, the prevalence of eye diseases such as glaucoma, cataracts, and macular degeneration, the surge in ophthalmic drug demand, and the increase in investment in research and development activities by various healthcare companies are the key factors driving the growth of the global ophthalmic drugs market.

The growth in ophthalmic drug demand, greater healthcare awareness to lower the risk of eye problems, and government initiatives to study and create new combinations of ophthalmic pharmaceuticals are also driving the market. The retinal disease segment dominated the global ophthalmic drugs market by type of indication and is expected to maintain this trend during the forecast period, owing to the rise in the geriatric population, the prevalence of macular degeneration, and the surge in sales of ophthalmic drugs for the treatment of retinal disease. However, the glaucoma segment is expected to grow significantly throughout the forecast period due to rising glaucoma prevalence, rising demand for ophthalmic medications, and increased awareness of glaucoma prevention and treatment.

North America accounted for a significant portion of the global market for ophthalmic drugs and is expected to maintain its leadership during the forecast period due to the rising prevalence of the elderly population, the rise in the prevalence of eye disease, and government initiatives for eye health.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Ophthalmic Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Ophthalmic Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Ophthalmic Drugs Market:
• Aerie Pharmaceuticals, Inc.
• Allergan
• Valeant Pharmaceuticals International, Inc.
• Bayer AG
• Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• Actavis Generics (Teva Pharmaceutical Industries Ltd.)
(Note: The list of the major players will be updated with the latest market scenario and trends)

Ophthalmic Drugs Market Segmentation:
By Product Type
• Prescription Drugs
• OTC Drugs
By Therapeutic Class
• Anti-inflammatory Drugs
   o NSAIDs
   o Steroids
• Anti-infective Drugs
   o Anti-fungal Drugs
   o Anti-bacterial Drugs
   o Others
• Anti-glaucoma Drugs
   o Alpha Agonist
   o Beta Blockers
   o Prostaglandin Analogs
   o Combined Medication
   o Others
• Anti-allergy Drugs
   o Anti-VEGF Agents
   o Others
By Disease Indication
• Dry Eye
• Glaucoma
• Infection/ Inflammation
• Retinal Disorders
  o Wet AMD
  o Dry AMD
  o Diabetic Retinopathy
  o Others
• Allergy
• Uveitis
• Others
By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Independent Pharmacies & Drug Stores
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Ophthalmic Drugs Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Ophthalmic Drugs Market By Product Type, By Therapeutic Class, By Disease Indication, Distribution Channel and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Global Ophthalmic Drugs Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Ophthalmic Drugs Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Ophthalmic Drugs Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Global Ophthalmic Drugs Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Prescription Drugs
   7.2. OTC Drugs

8. Global Ophthalmic Drugs Market, By Therapeutic Class Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Anti-inflammatory Drugs
        8.1.1. NSAIDs
        8.1.2. Steroids
   8.2. Anti-infective Drugs
        8.2.1. Anti-fungal Drugs
        8.2.2. Anti-bacterial Drugs
        8.2.3. Others
   8.3. Anti-glaucoma Drugs
        8.3.1. Alpha Agonist
        8.3.2. Beta Blockers
        8.3.3. Prostaglandin Analogs
        8.3.4. Combined Medication
        8.3.5. Others
   8.4. Anti-allergy Drugs
        8.4.1. Anti-VEGF Agents
        8.4.2. Others

9. Global Ophthalmic Drugs Market, By Disease Indication Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Dry Eye
   9.2. Glaucoma
   9.3. Infection/ Inflammation
   9.4. Retinal Disorders
        9.4.1. Wet AMD
        9.4.2. Dry AMD
        9.4.3. Diabetic Retinopathy
        9.4.4. Others
   9.5. Allergy
   9.6. Uveitis
   9.7. Others

10. Global Ophthalmic Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)  
    10.1. Hospital Pharmacies
    10.2. Online Pharmacies
    10.3. Independent Pharmacies & Drug Stores

11. North America Ophthalmic Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. U.S.A
          11.2.2. Canada
          11.2.3. Mexico
    11.3. Market Size (USD Million) Forecast for North America 2022-2028

12. Latin America Ophthalmic Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Brazil
          12.2.2. Venezuela
          12.2.3. Argentina
          12.2.4. Rest of Latin America
    12.3. Market Size (USD Million) Forecast for Latin America 2022-2028

13. Europe Ophthalmic Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Germany
          13.2.2. U.K         
          13.2.3. France
          13.2.4. Italy
          13.2.5. Spain
          13.2.6. Russia
          13.2.7. Poland
          13.2.8. Rest of Europe
    13.3. Market Size (USD Million) Forecast for Europe 2022-2028

14. Asia Pacific Ophthalmic Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Japan
          14.2.2. China
          14.2.3. India
          14.2.4. Australia and New Zealand
          14.2.5. ASEAN
          14.2.6. Rest of Asia Pacific
    14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          15.2.1. GCC
          15.2.2. Israel
          15.2.3. South Africa
          15.2.4. Rest of MEA
    15.3. Market Size (USD Million) Forecast for MEA 2022-2028

16. Market Share Analysis and Competitive Landscape   
    16.1. Global Landscape - Key Players, Revenue and Presence
    16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    16.3. Global Emerging Companies
    16.4. North America - Market Share Analysis and Key Regional Players
    16.5. Europe - Market Share Analysis and Key Regional Players
    16.6. Asia Pacific - Market Share Analysis and Key Regional Players
    16.7. Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    17.1. Aerie Pharmaceuticals, Inc.
         17.1.1. Company Overview
         17.1.2. Product Portfolio
         17.1.3. SWOT Analysis
         17.1.4. Financial Overview
         17.1.5. Strategic Overview
    17.2. Allergan
         17.2.1. Company Overview
         17.2.2. Product Portfolio
         17.2.3. SWOT Analysis
         17.2.4. Financial Overview
         17.2.5. Strategic Overview
    17.3. Valeant Pharmaceuticals International, Inc.
         17.3.1. Company Overview
         17.3.2. Product Portfolio
         17.3.3. SWOT Analysis
         17.3.4. Financial Overview
         17.3.5. Strategic Overview
    17.4. Bayer AG
         17.4.1. Company Overview
         17.4.2. Product Portfolio
         17.4.3. SWOT Analysis
         17.4.4. Financial Overview
         17.4.5. Strategic Overview
    17.5 Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
         17.5.1. Company Overview
         17.5.2. Product Portfolio
         17.5.3. SWOT Analysis
         17.5.4. Financial Overview
         17.5.5. Strategic Overview          
    17.6 Novartis AG
         17.6.1. Company Overview
         17.6.2. Product Portfolio
         17.6.3. SWOT Analysis
         17.6.4. Financial Overview
         17.6.5. Strategic Overview      
    17.7. Pfizer Inc.
         17.7.1. Company Overview
         17.7.2. Product Portfolio
         17.7.3. SWOT Analysis
         17.7.4. Financial Overview
         17.7.5. Strategic Overview
    17.8. Regeneron Pharmaceuticals, Inc.
         17.8.1. Company Overview
         17.8.2. Product Portfolio
         17.8.3. SWOT Analysis
         17.8.4. Financial Overview
         17.8.5. Strategic Overview
    17.9. Santen Pharmaceutical Co., Ltd.
         17.9.1. Company Overview
         17.9.2. Product Portfolio
         17.9.3. SWOT Analysis
         17.9.4. Financial Overview
         17.9.5. Strategic Overview
    17.10. Actavis Generics (Teva Pharmaceutical Industries Ltd.)
         17.10.1. Company Overview
         17.10.2. Product Portfolio
         17.10.3. SWOT Analysis
         17.10.4. Financial Overview
         17.10.5. Strategic Overview

18. Pre and Post COVID-19 Impact
    18.1. Positive influence on the healthcare industry
    18.2. The financial disruption of the manufacturing sector
    18.3. Impact of COVID-19 on emerging companies
    18.4. Significant mandates in the healthcare regulations initiated by administrations
    18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client

Tables

Figures